Selsick, Hugh
Heidbreder, Anna
Ellis, Jason
Ferini-Strambi, Luigi
García-Borreguero, Diego
Leontiou, Chrysoula
Mak, Michael S.B.
O’Regan, David
Parrino, Liborio
Funding for this research was provided by:
Idorsia Pharmaceuticals
Article History
Received: 28 December 2023
Accepted: 10 April 2024
First Online: 26 April 2024
Declarations
:
: HS declares receiving payment for sitting on an Idorsia advisory board, receiving consulting fees from Alturix and receiving honoraria/payment for lectures by Alturix, Idorsia, and Jazz. AH declares receiving honoraria for lectures from Idorsia and Inspire, and participation in an Idorsia advisory board. JE reports support from grants/contracts on behalf of Northumbria University from Sleep Cogni, Unilever, RB PHE, Elizabeth Casson Foundation, Pukka, Mayborn, and Alzheimer’s UK; receiving consulting fees from NHS England Education North East, Nottingham NHS Trust, NUTH, Salience, Northumberland NHS Trust, Gateshead NHS Trust, RoSPA, and South Cumbria NHS Trust; receiving payment/honoraria from Emma, Grayrock, and Idorsia Pharmaceuticals; and leadership or fiduciary roles with British Sleep Society, Sleep Research Society, and Sleep Research and Consulting Ltd. LFS reports receiving consulting fees from Bayer and Bioproject; and receiving payment or honoraria from Lundbeck, Angelini Pharma, Idorsia, Bruno Farmaceutici, Italfarmaco, Sanofi, Bioproject, and Jazz Pharma. DGB reports receiving honoraria/payment for lectures from Idorsia. CL is employed by Idorsia. MM reports receiving grants from Paladin, Jazz and Esai through the University of Toronto; and receiving payment for honoraria/lectures from Esai and Sunovion. DO reports receiving payment/honoraria from the British Association of Psychopharmacology, Neurodiem, TEVA and Idorsia; having patents planned/issued/pending and stock/stock options with Closed Loop Medicine; participation on the Redefining Education in Sleep Training advisory board; and is President of the Sleep Section, Royal Society of Medicine. LP reports receiving consulting fees from Idorsia.
: This research was approved by Pearl IRB, Protocol #22-IPSO-176 and determined exempt in accordance with FDA 21 CFR 56.104 and DHHS 45CFR46.104(d)(2):(2) Tests, Surveys, Interviews on 20 December 2022. Participants indicated consent by choosing to proceed with completing the survey after completing the initial screening questions.
: Not applicable.